logo
Letter: Call for transparency and fairness in land use and property valuations

Letter: Call for transparency and fairness in land use and property valuations

The Citizen15-05-2025

Letter: Call for transparency and fairness in land use and property valuations
Alex Forster writes via email:
Thank you MMC Sizwe for presenting the Land Use Scheme at the Heidelberg Town Hall on May 7, providing the community with an opportunity to voice their concerns regarding land use.
Additionally, I thank you for providing a platform through which concerned community members and stakeholders have 28 days to raise their concerns and complaints to your office via email, and for assuring that these community concerns will be addressed and the necessary attention afforded to each concern/complaint.
Firstly, as was pointed out in the presentation, the writing on the presentation handed out to attendees is so small that one cannot read the presentation, even using a magnifying glass.
Secondly, the community was only notified of the presentation on short notice.
Had the notification of the presentation been a little earlier on the website, it would have enabled the community to table pertinent concerns or complaints. I heard of the presentation on May 6.
As Mr Wiersma pointed out, the public notification was only placed on the Lesedi website on the April 29.
I feel I did not express myself fully at the presentation and will therefore use this opportunity to table the concerns/complaints of affected smallholder property owners.
Smallholder title deeds expressly limit the number of dwelling houses built on each smallholding.
As Mr Loydd, the town planner, informed us: 'Should a property owner wish to build additional dwellings, the municipality must be notified and authorisation should be obtained from the municipality'.
I was shocked when one lady voiced her concerns regarding 72 rooms built for student accommodation on a residential property; buildings being erected 22cm from the border with another residential property, and buildings being erected within the flood line boundary.
This revelation immediately brought to mind a writing in the September 16, 2024, of the Citizen Newspaper, 'Densification is eroding the quality of life'. This writing indicates that three dwellings erected on a residential plot are acceptable to municipalities and, for that matter, the building of 72 rooms for student accommodation on a plot is equally acceptable.
The writing points out that the interests of developers take precedence over the rights of residents.
Smallholder title deeds expressly restrict the number of animals which one may keep on a smallholding.
An exceeding great concern is how Lesedi can start charging smallholders increased property tariffs of between 300% and 900%?
The Lesedi Municipality would like the smallholder to believe that keeping 10 chickens on the smallholding means that such property is being expressly used for residential purposes, and therefore, the municipality is entitled to increase the property rates with these exorbitant increases. The municipality justifies charging small holders the 1:1 residential property rate instead of the 1:0.25 rate applicable to the agricultural properties rate.
How is it that Lesedi advises those concerned smallholder property owners that this was communicated to them in a section 49 notification?
This is not true.
Those very few smallholders who did receive the section 49 notification were not alerted to the fact that rates would increase by between 300% and 900%.
The section 49 notification reads as follows: 'Kindly note that your property location of agricultural holding —— AH is now valued at R…… and categorised as residential properties, and will commence to bill property rates on the above value as from July 1, 2024'.
Here I would like to bring to your attention that in the 2019-2023 Valuation Roll where the smallholder properties were already categorised as residential.
The smallholder is still categorised as residential on the 2024-2029 Valuation Roll
So, once again, I ask why the 300% to 900% tariff increases on smallholders?
I again think of the Citizen News writing: 'Densification is eroding the quality of life', and I think of the gentleman and the lady at the Land Use Presentation who were expressing their first-hand experience of how this densification of residential properties is happening and how it is adversely affecting:
1. The ability to sell properties
2. Lack of proper hygienic sewerage systems
3. Presence of open and raw sewerage running through properties
4. Absence of street lights
5. Neglect of cutting the grass
6. Infiltration of crime, which densification allows into the area
7. Absolute destruction of the quality of life needed to sustain healthy living areas to attract investment and promote economic growth in the area.
On behalf of all smallholders, I respectfully request that Lesedi speedily address the smallholders' assessment rates dilemma, and just as speedily rectify what is obviously an injustice to all smallholders, and to revoke the current 2024-2029 Valuation Roll.
MMC Sizwe, I note your willingness to assist property owners and the promise to address all issues. I thank you for encouraging concerned property owners and stakeholder attendees to email concerns to your office.
You have assured the Land Use Presentation attendees that emails will be answered, not like the gentleman who raised the concern that an email informing your office of building rubble on the pavement. A year later, the rubble is still on the pavement, and his email was not been responded to.
I will therefore cc many of the concerned community members and stakeholders I know of, and encourage each one to take up your offer. Additionally, I urge each property owner affected by the assessment rate hike to assist as much as they can in the remedying of the assessment rate contention.
At Caxton, we employ humans to generate daily fresh news, not AI intervention. Happy reading!

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Kendrick Lamar's ‘GNX' Wins Album of The Year at The 2025 BET Awards
Kendrick Lamar's ‘GNX' Wins Album of The Year at The 2025 BET Awards

Yahoo

time18 minutes ago

  • Yahoo

Kendrick Lamar's ‘GNX' Wins Album of The Year at The 2025 BET Awards

Kendrick Lamar took home the award for Album of the Year at the 2025 BET Awards, beating out Beyoncé, The Weeknd, Drake, and more, and adding to the impressive string of accolades for the L.A. rapper following his now-infamous feud with Drake. His award was presented to him by actor Keke Palmer. During his acceptance speech, he acknowledged that he hasn't often attended the BET Awards in recent years, but said it's always been important to him. 'I ain't been here in a long time,' he said, 'BET always makes sure that they represent the culture right, and always put me in the midst of the cycle of what we represent, and that's real, true down to Earth music that people can feel. So I always give my heart to BET.' He looked towards the back of the crowd and showed out 'All my L.A. natives' before thanking God and his company, PG Lang. More from Rolling Stone Teyana Taylor Makes the BET Awards Her 'Escape Room' in Fiery Performance Lil Wayne Wows the BET Awards With 'A Milli' Performance Doechii Slams Trump's L.A. Protest Crackdown While Accepting BET Award He also shouted out SZA, who was also in attendance and added, 'We on tour right now, please come to the show.' They are in fact in the middle of their Grand National tour, which finishes its North American dates this month and hits Europe in July. Lamar, who is the night's most nominated act, was handed a slew of additional trophies by host Kevin Hart, though the particulars of the awards were not named. Best of Rolling Stone Sly and the Family Stone: 20 Essential Songs The 50 Greatest Eminem Songs All 274 of Taylor Swift's Songs, Ranked

Sly Stone's Music Formed The Backdrop To Several Hip-Hop Classics
Sly Stone's Music Formed The Backdrop To Several Hip-Hop Classics

Black America Web

time19 minutes ago

  • Black America Web

Sly Stone's Music Formed The Backdrop To Several Hip-Hop Classics

Sly Stone, a legendary musician who helped propel funk to its elevated heights in the realm of Black music, has died. Hip-Hop artists of various eras have sampled Sly Stone's work over the years, and we've got a playlist highlighting some of those audio classics. As Hip-Hop Wired reported earlier, Sly Stone, born Sylvester Stewart in Denton, Texas, passed away Monday (June 9) at the age of 82. After establishing his roots in the Bay Area as a musical prodigy, Stone ventured into becoming a front-facing artist with his Sly and The Stones in the 1960s with the late Cynthia Robinson, the trumpeter who was a founding member of Sly and the Family Stone, the band that catapulted Stone into the annals of music history. Alongside fun pioneers such asJames Brown and Parliament-Funkadelic, Stone and his band enjoyed a successful run of album releases extending into the late 1970s. Stone's life was captured in the 2023 biography, Thank You (Falettinme Be Mice Elf Agin), written with Ben Greenman, featuring a foreword from Ahmir 'Questlove' Thompson. Thompson also produced the stirring 2025 documentary centered on Stone's life and legacy, Sly Lives! (aka the Burden of Black Genius) . Hip-Hop artists such as LL Cool J, Queen Latifah, The Jungle Brothers, Public Enemy, and scores more dug into the crates to grab bits of Stone's music to form the backdrop of their works. Below, we've got a handful of those songs featured in the playlist below. Long live Sly Stone. May he rest powerfully in peace. — Photo: Michael Putland / Getty Sly Stone's Music Formed The Backdrop To Several Hip-Hop Classics was originally published on Samples 'Trip To Your Heart.' Samples 'Dance to the Music.' Samples 'You Can Make It If You Try.' Samples 'Sing A Simple Song.' Samples 'Everyday People.' Black America Web Featured Video CLOSE

AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease
AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease

Yahoo

time19 minutes ago

  • Yahoo

AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease

Seongnam-si, South Korea and Abu Dhabi, UAE, June 09, 2025 (GLOBE NEWSWIRE) -- AriBio Co., Ltd. ("AriBio"), a South Korean biopharmaceutical company specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi (collectively 'Arcera'), today announced the signing of exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer's disease. Under the terms of the agreements, Arcera will have exclusive rights to commercialize AR1001 in its key markets, including Latin America, the Middle East, Southern Africa, Ukraine and select Eurasian countries. AriBio will be responsible for manufacturing and supplying the product. The total deal value is estimated at USD 600 million across the development, launch and commercialization period, contingent upon the achievement of certain milestones. AR1001 is a novel, disease-modifying, once-daily oral phosphodiesterase-5 (PDE5) inhibitor currently being studied in a global Phase 3 clinical trial (POLARIS-AD) for the treatment of early-stage Alzheimer's disease. The enrollment target for the Phase 3 trial has been reached, and the topline results are expected in the first half of 2026. Facilitated by the Korea Development Bank (KDB) and aligned with the Korean government's policy to foster the biohealth industry, this collaboration represents a significant step forward to enhance the global competitiveness of Korea's pharmaceutical and biotech industry. "This partnership with Arcera marks a significant milestone in our mission to bring innovative treatments to patients worldwide," said Jai Jun Choung, CEO of AriBio. "Arcera's strong commercial capabilities and deep understanding of the high-growth markets make them an ideal partner to advance AR1001 in these important regions." "We are excited to enter into this collaboration with AriBio, which will provide access to AR1001, a novel treatment, for patients across these countries," said Isabel Afonso, CEO of Arcera. "This agreement aligns with our strategy to expand our neuroscience portfolio and reinforces our commitment to providing access to novel therapies in regions with significant unmet medical needs." The agreement underscores both companies' dedication to addressing unmet medical needs in neurodegenerative diseases and enhancing patient access to innovative therapies globally. This deal follows the Memorandum of Understanding signed between AriBio and Arcera in March 2025, where both parties agreed to strengthen their partnership by actively exploring strategic investments, and advancing joint research and development based on shared interests. ENDS About AriBio Co., Ltd. Founded in 2010, AriBio is a clinical-stage biopharmaceutical company headquartered in South Korea, with offices located in the United States to manage global clinical operations and regulatory affairs. The company focuses on the development of novel therapies for neurodegenerative diseases, including Alzheimer's disease. AriBio continues to expand its partnerships to accelerate the development and delivery of life-changing treatments to patients worldwide. About Arcera Arcera is a global life sciences company, headquartered in Abu Dhabi. Arcera develops, manufactures, and commercializes a broad range of high-quality proven and innovative medicines in key international markets. Its portfolio exceeds 2,000 medicines covering wide therapeutic areas which reach patients in ninety countries in four continents, backed by manufacturing and packing sites across the world. Arcera was established by the sovereign wealth fund, ADQ to realize Abu Dhabi's ambition as a global leader in innovative and sustainable healthcare. To learn more about Arcera, visit Attachment AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease CONTACT: Tanya Xi, MD, PhD, MBA, Senior Director, Business Development & Medical Affairs, AriBio (US) AriBio Co., Ltd. tanyaxi@ Rafael Ferrer, SVP Corporate Development. Arcera rferrer@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store